Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Research & Development (2016 - 2026)

Anika Therapeutics has reported Research & Development over the past 17 years, most recently at $6.7 million for Q1 2026.

  • Quarterly Research & Development rose 10.79% to $6.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $26.4 million through Mar 2026, up 4.88% year-over-year, with the annual reading at $25.8 million for FY2025, 0.88% up from the prior year.
  • Research & Development was $6.7 million for Q1 2026 at Anika Therapeutics, up from $6.5 million in the prior quarter.
  • Over five years, Research & Development peaked at $8.9 million in Q2 2023 and troughed at -$3.3 million in Q4 2023.
  • The 5-year median for Research & Development is $6.5 million (2024), against an average of $5.8 million.
  • Year-over-year, Research & Development plummeted 135.2% in 2022 and then soared 294.7% in 2024.
  • A 5-year view of Research & Development shows it stood at -$2.1 million in 2022, then tumbled by 58.24% to -$3.3 million in 2023, then soared by 294.7% to $6.5 million in 2024, then dropped by 0.85% to $6.5 million in 2025, then rose by 4.05% to $6.7 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Research & Development are $6.7 million (Q1 2026), $6.5 million (Q4 2025), and $6.9 million (Q3 2025).